AndroGel for Men 65+: Managing Testosterone Therapy in Geriatric and Transitioning-to-Adult-Care Patients

What Is the FDA-Approved Geriatric Labeling for AndroGel?

The FDA-approved prescribing information for AndroGel states that clinical studies of testosterone gel did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger men. The label advises that testosterone is used with caution in elderly patients, given that older men have a higher baseline prevalence of benign prostatic hyperplasia and prostate cancer. The full FDA prescribing information is publicly available at the FDA accessdata portal.

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy in men with hypogonadism specifies a serum total testosterone threshold of 300 ng/dL as the lower boundary for diagnosis and states that clinicians should aim for mid-normal range levels (400 to 700 ng/dL) in treated patients. The guideline notes that older men warrant individualized benefit-risk discussions before therapy is started. Read the full guideline at the Journal of Clinical Endocrinology and Metabolism.

Why Geriatric Patients Differ Pharmacokinetically

Testosterone clearance slows modestly with age due to reduced hepatic blood flow and declining sex hormone-binding globulin (SHBG) variability. Free testosterone, the biologically active fraction, may be disproportionately affected by SHBG changes. A 2017 analysis published in the Journal of Clinical Endocrinology and Metabolism found that SHBG rises roughly 1.2% per year after age 40, meaning total testosterone measurements alone may overestimate bioavailable hormone in older men. See Travison et al. For the SHBG-aging relationship.

Transdermal absorption of AndroGel also varies more widely in older men because skin thickness and hydration decline with age. Clinicians should measure serum testosterone 2 to 8 hours after application to capture peak levels accurately.

Distinguishing Pathologic Hypogonadism from Age-Related Decline

Serum testosterone falls an average of 1 to 2% per year after age 30. By age 70, roughly 20% of men have total testosterone below 300 ng/dL, rising to 30% by age 80 according to the European Male Aging Study (N=3,369). See Wu et al., NEJM 2010 for the EMAS prevalence data. The clinical diagnosis of hypogonadism requires both a confirmed low morning serum testosterone on two separate occasions and the presence of symptoms such as reduced libido, erectile dysfunction, fatigue, or loss of muscle mass. Age-related decline alone, in the absence of symptoms, is not an FDA-approved indication.

What the Testosterone Trials Showed for Men 65+

The Testosterone Trials (TTrials) were a coordinated set of seven placebo-controlled trials conducted at 12 U.S. Sites specifically in men aged 65 and older with confirmed hypogonadism (testosterone <275 ng/dL) and age-related symptoms. Participants applied testosterone gel daily and were followed for 12 months. Full results are available via NEJM and its linked trial publications.

Sexual Function Trial Results

The Sexual Function Trial (N=470) found that testosterone gel improved sexual activity, sexual desire, and erectile function compared with placebo. The sexual activity score increased by 2.3 points (on a 12-point scale) more than placebo (P<0.001). This is a statistically meaningful but modest effect size, and clinicians should counsel patients accordingly.

Physical Function Trial Results

The Physical Function Trial (N=788) found no statistically significant benefit for walking speed or self-reported physical function at 12 months. Leg press strength did improve by approximately 13.5 kg more than placebo, suggesting a selective anabolic effect that did not translate to functional performance measures in this population. See Snyder et al., NEJM 2016.

Bone Density Trial Results

The Bone Trial (N=211) showed that testosterone gel significantly increased volumetric bone mineral density in the spine (7.5% more than placebo) and hip (4.1% more than placebo) over 12 months. Whether these gains reduce fracture risk long-term remains under study. See Snyder et al., JAMA Internal Medicine 2017.

Cardiovascular Findings in the TTrials

The TTrials reported a higher rate of noncalcified coronary artery plaque progression in the testosterone group compared with placebo (a mean increase of 41 mm³ vs. 14 mm³, P=0.002). This finding raised safety concerns that the TRAVERSE trial subsequently addressed. See Budoff et al., JAMA 2017.

TRAVERSE Trial: Resolving the Cardiovascular Debate

The TRAVERSE trial (N=5,246) was a randomized, placebo-controlled, non-inferiority trial in men aged 45 to 80 with hypogonadism and pre-existing cardiovascular disease or elevated cardiovascular risk. Participants used testosterone gel 1.62% titrated to maintain levels of 350 to 750 ng/dL. Median follow-up was 33 months. Full results were published in the New England Journal of Medicine in 2023.

The primary endpoint, major adverse cardiovascular events (MACE: nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death), occurred in 7.0% of the testosterone group and 7.3% of the placebo group. The hazard ratio was 0.96 (95% CI 0.78 to 1.17), confirming non-inferiority. Testosterone did not increase MACE risk in this high-risk geriatric cohort.

However, TRAVERSE also found that testosterone was associated with a higher incidence of atrial fibrillation (3.5% vs. 2.4%), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury (2.3% vs. 1.5%). These signals require clinical attention, particularly in men who already carry a diagnosis of atrial fibrillation or have a prior venous thromboembolic event. The FDA updated the testosterone prescribing label in 2023 to reflect the TRAVERSE findings. See the FDA Drug Safety Communication.

Dosing and Titration Protocol for Men 65+

Starting Dose Selection

The FDA-approved starting dose of AndroGel 1.62% is 40.5 mg (2 pump actuations) applied once daily to the upper arms and shoulders. For men 65 and older, many clinicians use this same starting dose, checking a serum testosterone level 14 days after initiation. The Endocrine Society 2018 guideline recommends dose adjustment to maintain testosterone in the mid-normal range (400 to 700 ng/dL). Guideline text at JCEM.

If the day-14 testosterone is below 350 ng/dL, the dose may be increased to 60.75 mg (3 actuations). If it exceeds 750 ng/dL, the dose should be reduced to 20.25 mg (1 actuation). Dose stability should be confirmed with a repeat measurement at day 28 before moving to quarterly monitoring.

Application Site Guidance for Older Skin

Older men may have drier, thinner skin over the upper arms. Application to clean, dry, intact skin immediately after a shower produces the most consistent absorption. Patients should allow the gel to dry for at least 5 minutes before dressing. Because secondary transference to women and children is a documented safety concern, the FDA label requires covering the application site with clothing. See the AndroGel Medication Guide at FDA.

Monitoring Schedule

| Timepoint | Tests Required | |-----------|---------------| | Baseline | Serum testosterone (×2, AM), LH, FSH, PSA, DRE, CBC, lipids, bone density (if indicated) | | Day 14 and 28 | Serum testosterone 2 to 8 h post-application | | 3 months | Serum testosterone, hematocrit, PSA | | 6 months | Serum testosterone, hematocrit, PSA, lipids | | Annually | All of the above plus DRE, bone density if osteoporosis risk present |

Hematocrit above 54% warrants dose reduction or temporary discontinuation. Per the Endocrine Society guideline, a hematocrit above 54% is the threshold for withholding therapy pending evaluation. Guideline reference.

Prostate Safety in Geriatric Patients

Prostate-specific antigen (PSA) and digital rectal examination are mandatory before starting AndroGel in any man over 40, and especially in men over 65. The Endocrine Society guideline contraindicates testosterone therapy in men with a PSA above 4 ng/mL without urologic evaluation, or in men with a PSA above 3 ng/mL who are at high risk for prostate cancer. Guideline.

A 2016 meta-analysis of 58 randomized controlled trials (N=5,898) published in the British Journal of Medicine found no significant increase in prostate cancer incidence among testosterone-treated men compared with placebo (RR 0.87, 95% CI 0.53 to 1.42). Cui et al., BJM systematic review. The Testosterone and Prostate Safety research gap remains, as no trial has been powered to detect a meaningful difference in prostate cancer incidence.

PSA Velocity as a Monitoring Signal

A PSA rise of more than 1.4 ng/mL above baseline within the first 12 months of therapy should prompt urology referral, regardless of absolute PSA value. Clinicians should document baseline PSA and re-check at 3 months and 12 months for the first year of treatment.

Polycythemia and Hematologic Monitoring

Testosterone stimulates erythropoietin production and increases red blood cell mass. Older men are at elevated baseline risk for polycythemia because erythropoietic reserve is already reduced by age. In the TRAVERSE trial, erythrocytosis (hematocrit >54%) occurred in 5.9% of testosterone users versus 1.5% of placebo users. TRAVERSE, NEJM 2023.

The risk is not trivial. Polycythemia raises blood viscosity and is associated with increased thromboembolic risk. For men who develop hematocrit between 50% and 54%, increased hydration and dose reduction should be tried first. Phlebotomy is reserved for hematocrit above 54% that does not respond to dose adjustment within 4 to 6 weeks.

Transition of Care: Ensuring Continuity for Geriatric TRT Patients

What "Transition to Adult Care" Means for 65+ Patients

For geriatric men, "transition to adult care" most often means transfer from a specialist (endocrinologist or urologist) to a primary care physician, or transfer between care settings such as from an outpatient practice to an assisted-living facility, inpatient hospitalization, or telehealth platform. These transitions carry real risk: testosterone gel may be omitted from medication reconciliation lists, doses may be transcribed incorrectly, or monitoring labs may lapse.

A 2020 analysis published in the Journal of the American Geriatrics Society found that medication discrepancies occurred in approximately 50% of older adults at care transitions, with hormonal and endocrine medications among the drug classes most frequently omitted. Kripalani et al., JAGS.

Medication Reconciliation Checklist for AndroGel at Transition

Receiving providers should verify all of the following within 90 days of accepting care:

• Current AndroGel formulation (1% vs. 1.62%), dose, and number of pump actuations
• Date of last serum testosterone measurement and the result
• Most recent hematocrit and PSA values
• History of any dose adjustments and the clinical reason
• Whether the patient has an active urology or endocrinology co-management relationship
• Contraindications review: atrial fibrillation history, prior DVT or PE, active prostate cancer, uncontrolled heart failure

The receiving clinician should order a repeat serum testosterone 2 to 8 hours after gel application within the first 30 days of assuming care if no lab result is available from the prior 3 months.

Telehealth and Pharmacy Continuity

When AndroGel is prescribed through a telehealth platform and the patient transitions to in-person care, the receiving physician needs direct access to the prescribing records and lab history. AndroGel 1.62% is a Schedule III controlled substance; some states restrict electronic prescribing of Schedule III drugs, so patients must carry a valid written prescription during care transitions to avoid a gap. DEA Controlled Substances Act reference via FDA.

Assisted Living and Long-Term Care Settings

In assisted-living and skilled nursing facilities, transdermal testosterone gels require special handling protocols. Staff must wear gloves when applying the gel to patients who cannot self-administer. Unused gel must be disposed of per facility hazardous waste policies. The risk of secondary exposure to female staff members or roommates is real: the FDA label documents cases of virilization in women and children after indirect contact. FDA label.

Absolute and Relative Contraindications in Men 65+

The FDA-approved label lists metastatic prostate cancer and male breast cancer as absolute contraindications to AndroGel. Additional considerations that carry particular weight in older men include:

• Untreated or poorly controlled obstructive sleep apnea (testosterone may worsen nocturnal hypoxemia)
• Hematocrit above 50% at baseline
• Symptomatic benign prostatic hyperplasia with urinary retention risk
• Poorly controlled congestive heart failure (fluid retention risk)
• History of venous thromboembolism not on anticoagulation

The Endocrine Society guideline states: "We recommend against starting testosterone therapy in patients with a hematocrit greater than 50%, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, or uncontrolled or poorly controlled heart failure." JCEM 2018.

Drug Interactions Relevant to Older Adults

Older men frequently take multiple medications. AndroGel carries documented interactions clinicians must review:

Warfarin: Testosterone may potentiate the anticoagulant effect of warfarin by inhibiting the metabolism of coagulation factors. INR should be checked more frequently after AndroGel is started, dose-adjusted, or discontinued. FDA label warning.

Insulin and oral hypoglycemics: Testosterone may improve insulin sensitivity, potentially lowering blood glucose. Men with type 2 diabetes on insulin or sulfonylureas should monitor glucose more closely after initiation.

Corticosteroids: Concurrent use with adrenocorticotropic hormone or corticosteroids may accelerate edema formation and warrant fluid monitoring.

Bone Health Considerations

Testosterone deficiency is an independent risk factor for osteoporosis in men. The National Osteoporosis Foundation recommends DEXA scanning in all men over 70, and in men over 50 with risk factors including hypogonadism. NOF guidelines via NCBI. The Bone Trial arm of the TTrials showed testosterone gel increased lumbar spine volumetric bone mineral density by 7.5% over 12 months, a clinically meaningful gain. JAMA Internal Medicine 2017.

Men on AndroGel who have baseline osteoporosis or a recent fragility fracture should also be evaluated for co-existing vitamin D deficiency and calcium insufficiency. Testosterone therapy alone does not fully substitute for bisphosphonate therapy in men with confirmed osteoporosis and fracture risk.

Sleep Apnea Screening Before and During Therapy

Testosterone therapy may worsen obstructive sleep apnea (OSA) by altering upper airway muscle tone and respiratory drive. A 2013 randomized crossover study in the Journal of Clinical Sleep Medicine (N=67) found that testosterone administration significantly increased the apnea-hypopnea index in men with pre-existing mild to moderate OSA. Liu et al., JCSM 2003. All men 65 and older should be screened for OSA symptoms (snoring, witnessed apneas, excessive daytime sleepiness) before therapy starts. Men with confirmed severe OSA should not receive testosterone until OSA is adequately treated with CPAP or equivalent therapy.